Universal CAR-T therapy: FDA allows trials for autoimmune diseases https://ymaho.com/universal-car-t-therapy-fda-allows-trials-for-autoimmune-diseases
FDA approved clinical trials of allogeneic CAR-T cell therapy QT-019C for lupus and scleroderma. Savings up to $100 billion, no chemotherapy. Learn about the breakthrough.
IMP761 — first LAG-3 agonist passes Phase I in autoimmune diseases https://ymaho.com/imp761-first-lag-3-agonist-passes-phase-i-in-autoimmune-diseases
Analysis of IMP761 data from Immutep at EULAR 2026: a new class of drugs for treating rheumatoid arthritis without total immunosuppression. Safety, mechanism, and prospects. Read more.
LAG-3 agonist IMP761: first clinical success in autoimmune diseases https://ymaho.com/lag-3-agonist-imp761-first-clinical-success-in-autoimmune-diseases
LAG-3 agonist IMP761 has shown clinical efficacy in suppressing T-cells for the first time. Learn about the revolution in treating autoimmune diseases without side effects. Read more.
Enspryng reduced the risk of relapses in MOGAD by 68% https://ymaho.com/enspryng-reduced-the-risk-of-relapses-in-mogad-by-68
Genentech proved the efficacy of satralizumab in a rare autoimmune disease. The risk of attacks decreased by 68%, new lesions by 79%. Learn how the first targeted drug fills the niche of empirical therapy.
CAR-T therapy for lupus: 100% remission in a small cohort https://ymaho.com/car-t-therapy-for-lupus-100-remission-in-a-small-cohort
German rheumatologists achieved 100% remission in lupus with CAR-T. Four-year data, immune reset mechanism, and forecasts. Read.
Tzield approved for children from 1 year: delaying type 1 diabetes https://ymaho.com/tzield-approved-for-children-from-1-year-delaying-type-1-diabetes
FDA expanded indications for teplizumab to children from one year. First drug capable of delaying diabetes for years at the preclinical stage. Learn how infusions change the prognosis for infants.
Saphnelo Pen approved by FDA: treating lupus at home https://ymaho.com/saphnelo-pen-approved-by-fda-treating-lupus-at-home
FDA approved Saphnelo subcutaneous pre-filled pens for lupus treatment. Patients can self-administer the drug without visiting a clinic. Learn about the breakthrough in therapy.
CAR-T therapy for lupus: FDA approval 2026 https://ymaho.com/car-t-therapy-for-lupus-fda-approval-2026
Analysis of FDA approval of the first CAR-T cell therapy for severe lupus. Key players, forecasts, and hidden risks. Find out who is leading the race.